NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Leuven, 11 March 2025 – Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center ...

Harvard Stem Cell Institute (HSCI) researchers, representing five Harvard departments and affiliated institutions as well as the Massachusetts Institute of Technology (MIT), have demonstrated that ...

A newly published review article highlights the critical role of fatty acid metabolism in shaping the tumor microenvironment and influencing cancer progression, offering fresh perspectives for the ...

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...